Sarepta Therapeutics Inc (SRPT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SRPT Giù? Forum Previsione Frazionamento azionario

Perché le azioni Sarepta Therapeutics Inc (SRPT) sono in ribasso?

Abbiamo notato un calo di 5.46% nelle azioni di Sarepta Therapeutics Inc (SRPT) durante la sessione di negoziazione di 2026-06-05. Sebbene ciò possa essere attribuito alla normale volatilità o a vari fattori interni ed esterni, tieni presente che stiamo monitorando attivamente la situazione e forniremo aggiornamenti tempestivi il prima possibile!

2023-06-23:

SRPT's stock fell 7.93% as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use.

https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-slumps-concerns-emerge-around-upcoming-gene-therapy-data-2023-06-23/

2023-04-13:

Before the market opened on Thursday, shares of Sarepta Therapeutics (NASDAQ: SRPT) experienced a decline of roughly 10% in pre-market trading. This drop occurred following a report stating that the U.S. Food and Drug Administration (FDA) staff had a leaning towards rejecting the company's Duchenne muscular dystrophy gene therapy, but a senior official intervened.

https://www.investing.com/news/stock-market-news/sarepta-tumbles-10-on-report-fda-leaned-toward-rejecting-duchenne-therapy-432SI-3054655

2023-03-17:

Sarepta Therapeutics's stock is going down today after the announcement of an advisory meeting for the SRP-9001's development (the first gene therapy) with the FDA, since their gene therapy isn't believed to be beneficial. The meeting comes as the company was preparing for the SRP-9001 regulatory action date on May 29, 2023.